熱門資訊> 正文

Tiziana股价在foralumab数据公布日上涨

2025-06-13 21:36

Tiziana Life Sciences plc(TLSA) 0

Tiziana Life Sciences (NASDAQ:TLSA) shares rose on Friday after the company said that its CEO, Ivor Elrifi, will present data related to its lead drug candidate, intranasal foralumab, for the treatment of neuroinflammation.
The CEO is set to give the oral presentation during the Bio International Convention in Boston for anti-CD3 monoclonal antibody, foralumab, on June 18, at 11:45 AM ET.
The stock is up 7% premarket.

More on Tiziana Life Sciences

Tiziana posts favorable PET scan data for lead asset in Alzheimer's
Tiziana rises on positive results in multiple sclerosis treatment study
Financial information for Tiziana Life Sciences

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。